<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355665</url>
  </required_header>
  <id_info>
    <org_study_id>CO-140121222102-SCCT</org_study_id>
    <nct_id>NCT02355665</nct_id>
  </id_info>
  <brief_title>Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Using a Naturalistic Clinical Model to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers Motivated to Quit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of a novel nicotine product
      for continuous abstinence from smoking. Efficacy of product will be evaluated by assessments
      of self-reported abstinence, verified by exhaled carbon monoxide (CO) levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 12</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 26</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 4</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 8</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 16</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Continuous Smoking Abstinence from Week 2</measure>
    <time_frame>at Week 20</time_frame>
    <description>Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Restlessness on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Anxiety on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Insomnia on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale</measure>
    <time_frame>at Week 2</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean number of daily doses at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean number of daily doses at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 3</time_frame>
    <description>Mean number of daily doses at Week 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean number of daily doses at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 5</time_frame>
    <description>Mean number of daily doses at Week 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean number of daily doses at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 7</time_frame>
    <description>Mean number of daily doses at Week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean number of daily doses at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 9</time_frame>
    <description>Mean number of daily doses at Week 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 10</time_frame>
    <description>Mean number of daily doses at Week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 11</time_frame>
    <description>Mean number of daily doses at Week 11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Mean Number of Daily Doses</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean number of daily doses at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean of Maximum number of daily doses at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean of Maximum number of daily doses at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 3</time_frame>
    <description>Mean of Maximum number of daily doses at Week 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean of Maximum number of daily doses at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 5</time_frame>
    <description>Mean of Maximum number of daily doses at Week 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean of Maximum number of daily doses at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 7</time_frame>
    <description>Mean of Maximum number of daily doses at Week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean of Maximum number of daily doses at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 9</time_frame>
    <description>Mean of Maximum number of daily doses at Week 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 10</time_frame>
    <description>Mean of Maximum number of daily doses at Week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 11</time_frame>
    <description>Mean of Maximum number of daily doses at Week 11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Daily Doses</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean of Maximum number of daily doses at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 3</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 5</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 7</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 9</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 10</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 11</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Number of Hourly Doses</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean of Maximum number of hourly doses at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of doses used after week 12</measure>
    <time_frame>through Week 26</time_frame>
    <description>Mean number of doses used after Week 12 through Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 1</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 2</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 4</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 6</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 8</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 12</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 16</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 20</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Self reported number of cigarettes smoked since last visit</measure>
    <time_frame>at Week 26</time_frame>
    <description>Subjects self-reports of the number of cigarettes smoked since last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Perception of the Product</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Perception of the Product</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Overall Perception of the Product</measure>
    <time_frame>at Week 12</time_frame>
    <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a scale of 1-5, where 1=not at all effective and 5=extremely effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a scale of 1-5, where 1=not at all effective and 5=extremely effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke</measure>
    <time_frame>at Week 12</time_frame>
    <description>Participants are asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a scale of 1-5, where 1=not at all effective and 5=extremely effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Speed of Action</measure>
    <time_frame>at Week 12</time_frame>
    <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Consistency in Perception</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Consistency in Perception</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Consistency in Perception</measure>
    <time_frame>at Week 12</time_frame>
    <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience of Use</measure>
    <time_frame>at Week 1</time_frame>
    <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience of Use</measure>
    <time_frame>at Week 6</time_frame>
    <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Distribution of the Participant Score for Product Convenience of Use</measure>
    <time_frame>at Week 12</time_frame>
    <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>through Week 26</time_frame>
    <description>Number of subjects with Adverse Events overall, and by system organ class, preferred term, and severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean systolic blood pressure at Week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean systolic blood pressure at Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean systolic blood pressure at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean systolic blood pressure at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean systolic blood pressure at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean systolic blood pressure at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean systolic blood pressure at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean systolic blood pressure at Week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean systolic blood pressure</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean systolic blood pressure at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean change from baseline in systolic blood pressure at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean diastolic blood pressure at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean diastolic blood pressure at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean diastolic blood pressure at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean diastolic blood pressure at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean diastolic blood pressure at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean diastolic blood pressure at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean diastolic blood pressure at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean diastolic blood pressure at Week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Diastolic Blood pressure</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean diastolic blood pressure at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure- Mean change from baseline</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean change from baseline in diastolic blood pressure at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean pulse at Week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean pulse at Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean pulse at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean pulse at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean pulse at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean pulse at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean pulse at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean pulse at Week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean pulse at Week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 1</time_frame>
    <description>Mean change from baseline in pulse at Week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 2</time_frame>
    <description>Mean change from baseline in pulse at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 4</time_frame>
    <description>Mean change from baseline in pulse at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean change from baseline in pulse at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 8</time_frame>
    <description>Mean change from baseline in pulse at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean change from baseline in pulse at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 16</time_frame>
    <description>Mean change from baseline in pulse at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 20</time_frame>
    <description>Mean change from baseline in pulse at Week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse- Mean Change from Baseline</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean change from baseline in pulse at Week 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Lips/Labial Mucosa</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Lips/Labial Mucosa (as assessed in the Visual Mouth Inspection) since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Buccal Mucosa</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Buccal Mucosa (as assessed in the Visual Mouth Inspection) since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Mucobuccal Fold</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Mucobuccal Fold (as assessed in the Visual Mouth Inspection) since baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Sublingual Mucosa</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Sublingual Mucosa (as assessed in the Visual Mouth Inspection) since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Gingiva</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Gingiva (as assessed in the Visual Mouth Inspection) since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Tongue</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Tongue (as assessed in the Visual Mouth Inspection) since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Hard/Soft palate</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Hard/Soft palate(as assessed in the Visual Mouth Inspection) since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with new or worsened conditions in Uvula/Oropharnyx</measure>
    <time_frame>at Week 6</time_frame>
    <description>Percentage of Participants with new or worsened conditions in Uvula/Oropharnyx(as assessed in the Visual Mouth Inspection) since baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight-Mean Change from baseline</measure>
    <time_frame>at Week 6</time_frame>
    <description>Mean Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight-Mean Change from baseline</measure>
    <time_frame>at Week 12</time_frame>
    <description>Mean Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight-Mean Change from baseline</measure>
    <time_frame>at Week 26</time_frame>
    <description>Mean Change from baseline in body weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match Nicotine spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Spray</intervention_name>
    <description>Nicotine Spray</description>
    <arm_group_label>Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match nicotine spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must be males or females 18-85 years of age who currently smoke cigarettes daily
        and are willing to stop smoking

        Exclusion Criteria:

        History of cardiovascular disease, stomach ulcer or diabetes unless physician's written
        approval is obtained.

        Use of other forms of tobacco/nicotine containing products other than cigarettes within 30
        days before baseline visit.

        Use of nicotine replacement therapies or other smoking cessation medicines/non-drug
        therapies within 30 days before the baseline visit.

        Pregnancy or intending to become pregnant.

        Hypersensitivity to the product, history of alcohol or substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Myers, MD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Clinical Trials</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>College Park</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <disposition_first_submitted>July 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2016</disposition_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

